insulin tregopil
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Dec 26, 2017 (NCT03430856)
Timeline
Indications
Mechanism of action
- Insulin receptorAGONIST
Insulin receptor agonist
- Insulin-like growth factor I receptorSupplementation
IGF1R supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108305 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04141423 | Phase 1 | Oct 28, 2019 | Biocon Limited, Profil GmbH |
| NCT03430856 | Phase 2/Phase 3 (Phase 3) | Dec 26, 2017 | Biocon Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocon Limited | For profit | 2 | 2 | 2 | 2017 |
| Profil GmbH | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1